December 29, 2011 — A budesonide/formoterol pressurized metered dose inhaler (pMDI) reduced chronic obstructive pulmonary disease (COPD) exacerbations more effectively than a formoterol dry powder ...

LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...

Lupin Limited is partnering with Spanish pharma company Laboratorios ERN SA to launch its fixed dose combination Luforbec ...

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ...

Lupin has announced a strategic collaboration with Spanish pharmaceutical company Laboratorios ERN S.A. for the launch of Luforbec (beclometasone/formoterol) 100/6, a fixed-dose combination inhaler.

Lupin Healthcare announces availability of the first carbon neutral pMDI with Luforbec ® 100/6 (beclometasone 100 mcg / formoterol 6 mcg) and establishes their commitment to supporting the NHS green ...

Lupin has partnered Spain's ERN to launch Luforbec for asthma and COPD, extending its respiratory franchise in Europe as the ...

AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...

Luforbec ® 100/6 (beclometasone 100mcg / formoterol 6mcg) pMDI, first branded generic alternative to Fostair ® 100/6 pMDI to treat Asthma & COPD, is now available in the UK Lupin continues their ...